NRG HN001/ Individualized Treatment for Naso-pharyngeal Carcinoma EBV positive/
Does testing levels of the virus EBV in a patient with cancer of the nasopharynx help
determine the best treatments?
Basic Study Information
Purpose:Location: University of Rochester
There are two study questions we are asking in this randomized phase II/III trial
based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for
locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first
undergo standard concurrent chemotherapy and radiation therapy. When this standard
treatment is completed, if there is no detectable EBV DNA in their plasma, then patients
are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy
or observation. If there is still detectable levels of plasma EBV DNA, patients will
be randomized to standard cisplatin and fluorouracil chemotherapy versus gemcitabine
and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs
used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride,
and paclitaxel work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading.
It is not yet known whether giving cisplatin and fluorouracil is more effective than
gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients
with nasopharyngeal cancer.
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Therese Smudzin
Phone: +1 585-275-7848
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search